International Flavors & Fragrances
IFF
$75.88
+5.30%
International Flavors & Fragrances Inc. (IFF) is the world's largest specialty ingredients producer, operating in the Chemicals - Specialty industry. The company creates proprietary formulations for flavors, fragrances, health, and food ingredients, serving the food, beverage, personal care, and pharmaceutical sectors globally. The current investor narrative centers on a potential operational turnaround and strategic repositioning, as the company navigates post-merger integration challenges and plans to divest its Food Ingredients business to sharpen its focus on higher-margin segments like Health & Biosciences, Scent, and Taste. Recent news highlights the stock being identified as oversold and poised for a rebound, suggesting a debate between its current undervaluation and the execution risks associated with its strategic pivot.…
IFF
International Flavors & Fragrances
$75.88
Related headlines
Investment Opinion: Should I buy IFF Today?
Rating: Hold. The core thesis is that IFF presents a high-risk, high-reward turnaround story where compelling valuation and technical factors are counterbalanced by significant fundamental and execution risks, warranting a neutral stance pending clearer evidence of operational stabilization.
Supporting evidence for this Hold rating includes: 1) A deeply depressed valuation, with a trailing PS ratio of 1.58 at the bottom of its historical range, suggesting limited further multiple compression. 2) A forward PE of 15.93x, which is likely at a discount to the specialty chemicals sector average, pricing in skepticism. 3) Positive analyst sentiment with recent upgrades, implying a consensus view of undervaluation. 4) Strong recent price momentum (+11.08% in 1 month) indicating buyer interest, though this is a technical, not fundamental, driver.
The rating would upgrade to a Buy under two conditions: 1) Concrete evidence of revenue stabilization or growth post the Food Ingredients divestiture announcement, and 2) a sustained expansion of gross margins above 31%. It would downgrade to a Sell if revenue decline accelerates beyond -8% YoY or if the ROE fails to turn positive over the next two quarters. Relative to its own battered history, the stock appears fairly valued for its current troubled state, but it is undervalued relative to its potential if the turnaround succeeds—a potential that remains unproven.
Sign up to view all
IFF 12-Month Price Forecast
IFF is a classic 'show me' story. The bullish setup—deep value, positive momentum, analyst support—is clear, but it is entirely contingent on the company demonstrating it can stop the bleeding and grow again. The base case of a volatile, range-bound stock is the most likely outcome as the market digests each step of the complex turnaround. The stance is neutral due to the high degree of binary execution risk. An upgrade to bullish would require two consecutive quarters of sequential revenue growth and expanding margins. A downgrade to bearish would be triggered by a breakdown below the $59.14 support level on worsening fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $98.64 and implied upside of +30.0% versus the current price.
Average Target
$98.64
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$61 - $99
Analyst target range
Analyst coverage for IFF is limited, with only 5 analysts providing estimates, which is low for a company of its market cap and suggests it may be flying under the radar of many institutional firms. The consensus sentiment, inferred from recent institutional ratings, leans bullish, with firms like Mizuho, Barclays, Wells Fargo, and Citigroup maintaining or initiating Buy/Overweight ratings as recently as February 2026. The average revenue estimate for the forward period is approximately $11.80 billion, with an average EPS estimate of $5.23. Without explicit price targets provided, the implied upside must be inferred from valuation multiples and analyst actions, which generally point to a positive outlook. The range of analyst estimates shows moderate uncertainty, with the high EPS estimate of $5.51 being 5.4% above the consensus and the low estimate of $5.09 being 2.7% below. The recent pattern of analyst actions includes an upgrade from Oppenheimer (to Outperform from Perform) in February 2026, which is a positive signal. However, the limited number of covering analysts means price discovery may be less efficient and the stock could be more susceptible to volatility from individual rating changes or corporate news.
Bulls vs Bears: IFF Investment Factors
The evidence currently tilts slightly towards the bullish case, primarily driven by extreme historical undervaluation, a powerful technical rebound from oversold levels, and a recent wave of analyst upgrades. However, the bearish arguments rooted in persistent revenue declines and poor capital efficiency are substantial and grounded in hard financial data. The single most important tension in the investment debate is whether the company's strategic pivot and portfolio optimization (divesting Food Ingredients) can successfully arrest the revenue decline and improve margins quickly enough to justify the current valuation recovery, or if the operational headwinds will persist, making the recent stock price surge another false dawn. The resolution of this execution risk will determine the stock's direction over the next 12 months.
Bullish
- Deeply Undervalued on Historical Basis: The stock's trailing Price-to-Sales ratio of 1.58 is near the bottom of its observable historical range, far below peaks above 12x seen in 2021. This extreme compression suggests the market has priced in substantial pessimism, offering a significant valuation cushion if the company's turnaround plans gain any traction.
- Strong Technical Momentum & Oversold Rebound: IFF is up 11.08% over the past month, significantly outperforming the SPY's 7.36% gain, signaling a powerful mean reversion rally from oversold conditions. The stock trades at 89.8% of its 52-week range, indicating strong momentum and proximity to a breakout above the $84.45 resistance level, which would confirm a new bullish phase.
- Analyst Consensus Bullish with Upgrade Catalyst: Recent institutional actions, including an upgrade from Oppenheimer to Outperform and Buy/Overweight ratings from Mizuho, Barclays, Wells Fargo, and Citigroup in February 2026, signal growing positive sentiment. The forward PE of 15.93x, based on an estimated EPS of $5.23, suggests the market is pricing in a recovery at a discount to typical sector multiples.
- Sequential Profitability Improvement: Q4 2025 net income of $18 million represents a positive swing from a net loss of $46 million in Q4 2024. While gross margin of 29.2% remains pressured, the sequential improvement from 29.0% in Q3 and a positive operating margin of 6.37% indicate early signs of operational stabilization amidst the strategic pivot.
Bearish
- Persistent Revenue Decline: Q4 2025 revenue of $2.589 billion declined 6.57% year-over-year, continuing a volatile multi-quarter downtrend from $2.844 billion in Q1 2025. This top-line pressure, even as the company plans to divest its largest segment (Food Ingredients at $802M), complicates the investment case and underscores fundamental deterioration.
- Negative Capital Efficiency Metrics: Return on Equity (ROE) is negative at -2.64% and Return on Assets (ROA) is a thin 2.06%, indicating highly inefficient use of shareholder capital. These figures highlight the deep operational challenges and the significant execution risk associated with the company's strategic transformation to improve returns.
- Margin Pressure and Earnings Volatility: The Q4 gross margin of 29.2% remains below the TTM gross margin of 30.95%, indicating ongoing competitive and cost pressures. Extreme earnings volatility is evident, with a net loss of $1.018 billion in Q1 2025 swinging to a net income of $612 million in Q2, creating significant uncertainty for investors.
- Chronic Underperformance vs. Market: With a 1-year price change of 4.66% versus the SPY's 34.9% gain, IFF has a relative strength of -30.24, highlighting a prolonged period of severe underperformance. This trend suggests the stock has been in a sustained downtrend that may not be fully reversed by the recent technical bounce.
IFF Technical Analysis
The stock is in a pronounced recovery phase from a significant drawdown, trading at approximately 75.88, which is 89.8% of its 52-week range (52-week high: 84.45, 52-week low: 59.14). This positioning near the upper end of the range indicates strong momentum but also suggests limited headroom before testing major resistance. The 1-year price change of 4.66% significantly underperforms the SPY's 34.9% gain, as shown by a relative strength of -30.24, highlighting a prolonged period of weakness now showing signs of reversal. Recent momentum is notably strong, with the stock up 11.08% over the past month and 5.86% over the past three months, both figures outpacing the broader market (SPY 1-month: 7.36%, 3-month: 2.67%). This acceleration in short-term gains, diverging positively from its weak 1-year trend, signals a potential trend reversal or a powerful mean reversion rally, likely fueled by oversold conditions and renewed investor interest. Key technical levels are clearly defined, with immediate resistance at the 52-week high of 84.45 and support at the 52-week low of 59.14. A breakout above 84.45 would confirm a new bullish phase, while a breakdown below 59.14 would invalidate the recovery thesis. The stock's beta of 1.032 indicates market-like volatility, but its recent price action and a high short ratio of 4.98 point to elevated speculative interest and the potential for sharp moves driven by covering activity.
Beta
1.03
1.03x market volatility
Max Drawdown
-27.4%
Largest decline past year
52-Week Range
$59-$84
Price range past year
Annual Return
+4.7%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | +11.1% | +9.5% |
| 3m | +5.9% | +2.7% |
| 6m | +19.0% | +5.8% |
| 1y | +4.7% | +34.9% |
| ytd | +11.5% | +4.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
Revenue growth remains challenged, with Q4 2025 revenue of $2.589 billion representing a year-over-year decline of 6.57%. The multi-quarter trend shows volatility, with revenue declining from $2.844 billion in Q1 2025, though segment data indicates the planned-for-divestiture Food Ingredients unit was the largest contributor at $802 million in the latest period, followed by Scent ($610M), Health & Biosciences ($589M), and Taste ($588M). This top-line pressure complicates the investment case, underscoring the need for successful portfolio optimization. Profitability is inconsistent but showing sequential improvement; the company reported net income of $18 million in Q4 2025, a positive swing from a net loss of $46 million in Q4 2024. The gross margin of 29.2% in Q4 improved from 29.0% in the prior quarter but remains below the trailing twelve-month gross margin of 30.95%, indicating ongoing margin pressure. The operating margin of 6.37% in Q4, while positive, reflects the operational challenges in a competitive ingredients market. The balance sheet and cash flow position appears manageable. The company maintains a moderate debt-to-equity ratio of 0.47 and a healthy current ratio of 1.42. Free cash flow for the trailing twelve months is $256 million, and operating cash flow for Q4 2025 was $318 million, which provides internal funding capacity. However, Return on Equity (ROE) remains negative at -2.64%, and Return on Assets (ROA) is a thin 2.06%, indicating inefficient use of capital and highlighting the need for the strategic transformation to yield better returns.
Quarterly Revenue
$2.6B
2025-12
Revenue YoY Growth
-0.06%
YoY Comparison
Gross Margin
+0.29%
Latest Quarter
Free Cash Flow
$256000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
Given the company's negative trailing net income and EPS of -$0.02, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 1.58, while the forward-looking metric, EV-to-Sales, is 2.25. The forward EV/Sales being higher than the trailing PS suggests the market is anticipating some revenue stabilization or growth ahead, though the expectation appears modest. Compared to industry averages, IFF's valuation presents a mixed picture. Its trailing PS ratio of 1.58 is difficult to contextualize without a precise sector average, but its forward PE of 15.93x, based on estimated future profitability, provides a clearer benchmark. If this forward PE is compared to a typical specialty chemicals sector average in the high teens to low 20s, IFF might be trading at a discount, reflecting skepticism about its growth and margin recovery. Historically, IFF's valuation has compressed significantly. The current PS ratio of 1.58 is near the bottom of its observable historical range, far below peaks above 12x seen in 2021. This suggests the stock is pricing in substantial pessimism, potentially offering a value opportunity if the company's turnaround plans gain traction, but also indicating the market has priced in fundamental deterioration from its post-merger highs.
PE
-46.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -651x~339x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on persistent top-line weakness and margin instability. Revenue has declined 6.57% YoY in Q4 2025, and the company remains reliant on the underperforming Food Ingredients segment, which contributed $802 million last quarter and is slated for divestiture, creating near-term revenue uncertainty. Profitability is highly volatile, with a net loss of $1.018 billion in Q1 2025 swinging to a $612 million profit in Q2, and capital efficiency metrics like the negative ROE of -2.64% indicate poor returns on invested capital. While free cash flow of $256 million (TTM) provides a buffer, the company must successfully execute its strategic refocus to stabilize earnings.
Market & Competitive Risks include valuation compression and sector-specific challenges. Although the current PS ratio of 1.58 appears low historically, it reflects the market's skepticism about growth; a failure to demonstrate a turnaround could keep the multiple depressed. The stock's beta of 1.032 indicates market-like volatility, but its high short ratio of 4.98 points to elevated speculative interest and the potential for sharp downdrafts on negative news. As a specialty chemicals company, IFF faces intense competition and potential customer consolidation, which could pressure pricing power and delay margin recovery, especially if the economic environment weakens.
Worst-Case Scenario involves a failure of the strategic pivot coupled with a broader market downturn. Specifically, the Food Ingredients divestiture could be delayed or executed at a disappointing price, Q4's modest profitability could reverse into renewed losses, and revenue declines could accelerate. This could trigger analyst downgrades from the currently bullish cohort and ignite covering by the significant short interest. In this adverse scenario, the stock could realistically re-test its 52-week low of $59.14, representing a downside of approximately -22% from the current price of $75.88. A breach of that level could lead to a fall towards the $50s, mirroring the stock's maximum drawdown of -27.41% observed in the provided data.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Continued revenue decline (-6.57% YoY) and poor capital efficiency (ROE -2.64%) threaten the viability of the turnaround thesis. 2) Execution Risk: The planned divestiture of the large Food Ingredients segment is complex and could be delayed or yield less proceeds than expected, disrupting the strategic pivot. 3) Market Risk: The stock's beta of 1.032 means it will likely fall with a declining market, and its high short ratio (4.98) increases volatility and the potential for sharp downdrafts on negative news. 4) Sentiment Risk: With only 5 covering analysts, the stock is susceptible to large price swings from individual rating changes.
The 12-month forecast is bifurcated, with a base case target range of $80-$90 (50% probability), a bull case of $95-$105 (30% probability), and a bear case of $59-$70 (20% probability). The base case, which is most likely, assumes a slow, grinding recovery where the company stabilizes but does not dramatically accelerate growth. This forecast is anchored by the current analyst EPS estimate of $5.23 and a forward PE in the mid-to-high teens. The key assumption is that management executes its strategic plan without major missteps, leading to moderate multiple expansion from today's depressed levels.
IFF is deeply undervalued relative to its own history, with a Price-to-Sales ratio of 1.58 sitting near the bottom of its range, far below historical peaks above 12x. Compared to sector peers, its forward PE of 15.93x also suggests a discount, reflecting the market's skepticism about its growth and margin recovery. The valuation implies the market expects continued operational challenges and has priced in significant pessimism. Therefore, the stock is undervalued if the turnaround succeeds, but fairly valued—or even still overvalued—if the fundamental deterioration continues.
IFF is a speculative buy, not a core holding. For investors with a high risk tolerance and a belief in management's turnaround plan, the current price offers an attractive entry point due to its historically low valuation (PS ratio 1.58) and bullish analyst sentiment. However, it is not a 'good buy' for conservative investors, as the key risks—persistent revenue decline and negative ROE—are substantial. The potential upside, inferred from a return to a higher valuation multiple and earnings recovery, is meaningful, but it is entirely contingent on successful execution, making it suitable only for a portion of a diversified portfolio.
IFF is unsuitable for short-term trading due to its fundamental volatility and the long-dated nature of its turnaround catalysts. It is best considered a long-term (2-3 year) speculative investment for investors who can withstand significant price swings. The company's strategic pivot will take multiple quarters to unfold, and the investment thesis hinges on improved financial metrics that will only become evident over time. The stock's market-like beta of 1.032 and lack of a meaningful dividend (yield 2.37%) further diminish its appeal for short-term holders or income investors.